N-(2-Pyrrolidino-aethyl)-o-phenylendiamin | 91636-55-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-Pyrrolidino-aethyl)-o-phenylendiamin
• 英文别名: 2-(2-pyrrolidinoethylamino)-aniline；2-N-(2-pyrrolidin-1-ylethyl)benzene-1,2-diamine
• CAS: 91636-55-4
• 化学式: C₁₂H₁₉N₃
• 分子量: 205.303
• InChiKey: XQOAOOXWHJJJNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-Pyrrolidino-aethyl)-o-phenylendiamin 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 Methyl 4-[[1-(2-pyrrolidin-1-ylethyl)benzimidazol-2-yl]carbamoyl]benzoate
  参考文献：
  名称：

  Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists

  摘要：

  Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith. Modeling studies of the recently published structures of KOR, DOR and MOR are used to explain the receptor selectivity. The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. The in vivo proof of principle for anti-nociceptive effect with a lead compound from this series is exemplified. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.064
• 作为产物：
  描述：

  1-(2-氨乙基)吡咯烷 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 N-(2-Pyrrolidino-aethyl)-o-phenylendiamin
  参考文献：
  名称：

  Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists

  摘要：

  Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith. Modeling studies of the recently published structures of KOR, DOR and MOR are used to explain the receptor selectivity. The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. The in vivo proof of principle for anti-nociceptive effect with a lead compound from this series is exemplified. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.064

文献信息

• Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity
  作者：Jerome C. Bressi、Ron de Jong、Yiqin Wu、Andy J. Jennings、Jason W. Brown、Shawn O’Connell、Leslie W. Tari、Robert J. Skene、Phong Vu、Marc Navre、Xiaodong Cao、Anthony R. Gangloff

  DOI：10.1016/j.bmcl.2010.03.092

  日期：2010.5

  A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[ 3-( 1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC(50)s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21(waf). Compound 5x displays efficacy in human tumor xenograft models. (C) 2010 Elsevier Ltd. All rights reserved.
• BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
  申请人：Nogra Pharma Limited

  公开号：US20150126553A1

  公开（公告）日：2015-05-07

  The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
• US4053472A
  申请人：——

  公开号：US4053472A

  公开（公告）日：1977-10-11
• Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists
  作者：Pradip K. Sasmal、C. Vamsee Krishna、S. Sudheerkumar Adabala、M. Roshaiah、Khaji Abdul Rawoof、Emima Thadi、K. Pavan Sukumar、Srisailam Cheera、Chandrasekhar Abbineni、K.V.L. Narasimha Rao、A. Prasanthi、Kamal Nijhawan、Mahaboobi Jaleel、Lakshmi Ramachandran Iyer、T. Krishna Chaitanya、Nirbhay Kumar Tiwari、N. Lavanya Krishna、Vijay Potluri、Ish Khanna、Thomas M. Frimurer、Michael Lückmann、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2014.12.064

  日期：2015.2

  Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith. Modeling studies of the recently published structures of KOR, DOR and MOR are used to explain the receptor selectivity. The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. The in vivo proof of principle for anti-nociceptive effect with a lead compound from this series is exemplified. (C) 2014 Elsevier Ltd. All rights reserved.